U.S. Oil and Gas Stock News

Wondering if Hercules Capital's share price really reflects what you are getting for your money? This breakdown walks through what the current market price might be missing or already pricing in. Recently, the stock closed at US$16.40, with returns of 2.2% over 7 days, 8.5% over 30 days, 4.0% over 1 year and 67.6% over both 3 and 5 years, while the year to date return sits at a 13.0% decline. These moves sit against a backdrop of ongoing interest in income focused business development...

Praxis Precision Medicines (NasdaqGS:PRAX) reported that the FDA accepted New Drug Applications for ulixacaltamide and relutrigine. The company is preparing for potential U.S. launches following these NDA acceptances. Praxis also highlighted clinical progress for elsunersen, adding to momentum across its late-stage pipeline. For readers tracking central nervous system drug developers, Praxis sits at an important point in its evolution, with ulixacaltamide and relutrigine moving into formal...

If you are wondering whether Gulfport Energy, at a last close of US$178.80, is attractively priced or if the easy gains are behind it, this article breaks down what the current share price might be implying about the stock's value. The stock has seen a 7.1% decline over the last week, a 13.9% decline over the last month, and a 13.3% decline year to date, set against a 94.6% return over the last 3 years and a 5.0% decline over the last year. Recent coverage has focused on Gulfport Energy's...

EIR Healthcare recently announced a partnership with MillerKnoll to integrate casework, furniture, and interior solutions directly into factory-built healthcare modules, aiming to deliver fully furnished, quality-checked clinics from day one. This move embeds MillerKnoll into an emerging offsite healthcare construction model that targets faster, more reliable delivery of behavioral health facilities funded by large public programs. We’ll now examine how embedding MillerKnoll’s solutions into...

For investors considering whether Cardinal Health's share price still offers value after a strong multi year run, this article explains what the current market price could be implying about the stock. The stock last closed at US$185.28, with returns of 27.2% over 1 year, 129.5% over 3 years and 270.6% over 5 years. This comes despite 7 day, 30 day and year to date returns of 3.9%, 12.9% and 9.9% declines respectively. Recent coverage around Cardinal Health has focused on its role as a major...

Why Element Solutions (ESI) is in focus after its latest earnings Element Solutions (ESI) recently reported first quarter results, with sales of US$840 million versus US$593.7 million a year earlier, while net income was US$55.9 million compared with US$98 million. See our latest analysis for Element Solutions. Even with a 4.45% 1-day share price decline to US$42.27 after earnings and a modest 7-day pullback, Element Solutions still sits on a 22.17% 1-month share price return and a 100.61%...

Aura Minerals reported record Q1 profits and record EBITDA, marking a turnaround from a loss in the prior year. The Board declared a dividend that exceeds the company's own minimum payout policy, indicating higher shareholder returns in the period. The stock, NasdaqGS:AUGO, last closed at $81.07, with very large 1 year and 3 year returns and a 62.1% gain year to date. For investors who have been tracking NasdaqGS:AUGO, this update focuses on fresh company news rather than past valuation...

Starboard Value LP has publicly pressed Lamb Weston Holdings (LW) to rethink its strategy, arguing that years of underperformance, a heavier cost base, and limited cost saving plans justify a reset in how the company operates. See our latest analysis for Lamb Weston Holdings. The latest activist pressure comes after a mixed period for the stock, with a 30 day share price return of 6.04% but a 1 year total shareholder return decline of 13.87%. This points to short term momentum set against a...

Warner Music Group (WMG) opened Q1 2026 with revenue of US$1.8 billion, basic EPS of US$0.33 and net income of US$174 million, setting the tone for how investors will read the latest update against a year of compressed margins. The company has reported quarterly revenue of US$1.63 billion in Q4 2024, US$1.87 billion in Q4 2025 and US$1.84 billion in Q1 2026. Over the same period, basic EPS has ranged from US$0.08 in Q4 2024 to US$0.45 in Q1 2025 and US$0.33 in the latest quarter, leaving...

Why Suncrete (RMIX) is on investors’ radar Suncrete (RMIX) has drawn attention after a strong share price move over the past month, with the stock returning 46.5% across that period and 34.6% over the past 3 months. See our latest analysis for Suncrete. That swing in momentum, with a 46.5% 1 month share price return and 35.1% year to date share price return, sits alongside a 39.4% 1 year total shareholder return at a latest close of $15.40. If Suncrete’s recent move has you thinking about...

Nu Holdings (NYSE:NU) has appointed Carl Rivera as Chief Product Officer. Rivera is tasked with integrating technology and design to support Nu’s global financial product development. The move comes as the company focuses on expanding beyond its core Latin American markets. For investors tracking NYSE:NU, the leadership change arrives with the stock at $14.26 and a 1 year return of 11.4%. Over 3 years, the return is around 7 times the initial value, while year to date the stock shows a...

Sana Biotechnology (SANA) is back in focus as CEO Steve Harr prepares to deliver a business overview and company update at the BofA Securities 2026 Healthcare Conference on May 12. See our latest analysis for Sana Biotechnology. At a share price of $3.50, Sana’s 7 day share price return of 6.38% and 30 day share price return of 11.11% contrast with a year to date share price decline of 16.47%. The 1 year total shareholder return of 93.37% sits against weaker 3 and 5 year total shareholder...

In late April 2026, FormFactor, Inc. reported first-quarter revenue of US$226.14 million and net income of US$20.38 million, and issued second-quarter guidance calling for revenue around US$240 million and net income per diluted share near US$0.46, alongside expectations for record quarterly revenue and higher margins. Management linked this momentum to strong demand for AI-related semiconductor testing and ongoing restructuring and capacity investments, while FormFactor also highlighted its...

If you are wondering whether Asana’s current share price reflects its true worth, this breakdown will help you weigh what the market is pricing in against what the fundamentals suggest. Asana’s stock last closed at US$7.05, with a 7 day return of 11.6% and a 30 day return of 13.7%. However, the year to date return of negative 45.6% and 1 year return of negative 59.1% highlight that many holders have faced a tough ride. Those recent moves sit against a backdrop of ongoing coverage around...

Raymond James Financial (NYSE:RJF) has rolled out its Client 360 platform and an artificial intelligence learning academy for financial advisors. The company is committing a reported US$1.1b to technology, including AI powered tools aimed at improving advisor productivity and client service. Raymond James has closed its acquisition of Clark Capital Management Group and introduced proprietary active ETFs to expand its asset management menu. For investors following wealth management and...

Kodiak Sciences (NasdaqGM:KOD) reported positive Phase 3 GLOW2 results for Zenkuda (tarcocimab tedromer) in diabetic retinopathy. The drug showed superiority over sham treatment, supporting a potential multi indication BLA submission. The update follows earlier focus on KSI-101 and adds fresh validation for Kodiak’s ABC platform in retinal disease. Kodiak Sciences, trading at $43.68, now has clinically meaningful Phase 3 data for Zenkuda that relates directly to its lead pipeline asset. The...

Zoetis (ZTS) has opened 2026 with Q1 revenue of US$2.3b and basic EPS of US$1.42, setting the tone for how investors read the latest earnings update. The company has seen quarterly revenue move from US$2.2b in Q1 2025 to US$2.3b in Q1 2026, while basic EPS shifted from US$1.41 to US$1.42 over the same period, giving you a clear view of how the top and bottom lines are tracking year on year. Against that backdrop, the focus now is on how sustainably Zoetis is converting this revenue into...

Sensata Technologies Holding plc has reported past first-quarter 2026 results showing sales of US$934.8 million and net income of US$87.1 million, alongside new second-quarter guidance and an update on its ongoing share repurchase program. Together, the stronger quarterly earnings, forward earnings guidance, and completion of a multi-year buyback provide fresh insight into how Sensata is balancing growth investment with returning capital to shareholders. Next, we will examine how Sensata’s...

Arcus Biosciences (RCUS) has been in focus after first quarter 2026 results, which showed revenue of US$17 million and a net loss of US$128 million, alongside several pipeline and collaboration setbacks. See our latest analysis for Arcus Biosciences. The share price has been volatile around the recent Q1 2026 update and pipeline news. The 1 month share price return is 12.28% and the 90 day share price return is 17.83%, while the 1 year total shareholder return of 190.50% contrasts with a...

Artificial intelligence in healthcare sits at the crossroads of powerful data, rising care costs, and a world focused on inflation, energy shocks, and supply chain shifts. While oil, rates, and trade headlines pull markets in different directions, AI tools that can improve accuracy, access, and affordability in medicine are drawing close attention. The Transformative AI Healthcare Stocks screener looks for companies using AI to sharpen diagnostics, personalise treatment, streamline clinical...

If you are wondering whether Veradermics’ current share price lines up with its underlying value, this article breaks down what the numbers may indicate about the stock. Veradermics recently closed at US$107.85, with returns of 8.9% over 7 days, 90.2% over 30 days and 185.7% year to date. This puts the current price action firmly in focus for valuation-minded investors. Recent coverage around Veradermics has centered on its position within the Pharmaceuticals industry and how investors are...

If you are wondering whether Darling Ingredients at around US$62 is offering fair value or a potential discount right now, this article breaks down what the current price may be implying about the stock. The share price is at US$62.27, with a 3.1% decline over the last 7 days and a 2.0% decline over 30 days, set against a 65.4% gain year to date and an 84.0% return over the past year. This mix of recent pullbacks and longer term gains can change how you think about both upside and...

Omega Healthcare Investors (NYSE:OHI) is selling CommuniCare’s skilled nursing assets to lower tenant concentration risk. The move is part of a broader portfolio cleanup that also considers financial pressures at Maplewood and Genesis. The company aims to support dividend stability and overall portfolio health as operator stress continues across the sector. For investors watching NYSE:OHI at a share price of $46.13, this portfolio cleanup follows a very large 3-year return and a 94.0%...

Why Chime Financial stock is back in focus Chime Financial (CHYM) just posted its first GAAP profitable quarter since listing, along with 25% year over year revenue growth, a new Chime Prime membership tier, and a completed US$200 million share repurchase program. See our latest analysis for Chime Financial. Despite reporting its first GAAP profitable quarter and approving US$200 million of buybacks, Chime's 1 day share price return of a 12.5% decline and year to date share price return of a...